Back

Journal of Neurology

22 training papers 2019-06-25 – 2026-03-07

Top medRxiv preprints most likely to be published in this journal, ranked by match strength.

1
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy
2026-01-30 neurology 10.64898/2026.01.29.26345179
#1 (5.9%)
Show abstract

BackgroundDisorders affecting the spinal cord (myelopathies) can cause severe disability. Despite diagnostic advances, approximately 12-18% of myelopathy cases continue to elude an etiological diagnosis, hampering effective treatment. MethodsThis retrospective, multicenter, tertiary care cohort study conducted from 2014 to 2025 evaluated archived biofluids from patients with IM, known autoimmune myelitis, or other neurological diseases (ONDs). Proteome-wide phage display was used to discover no...

2
Bodily self disturbances: a new clinical marker of persistent postural-perceptual dizziness
2026-02-01 neurology 10.64898/2026.01.30.26345201
#1 (5.5%)
Show abstract

Persistent Postural-Perceptual Dizziness (PPPD) is among the most prevalent chronic neuro-otologic disorders, affecting 15-20% of adults seen in neurology and specialized dizziness clinics. Classified as a functional vestibular disorder and defined by established diagnostic criteria, PPPD typically follows peripheral or central otoneurological disorders. However, the mechanisms underlying the transition from these disorders to chronic perceptual dizziness remain unclear. Beyond maladaptive postu...

3
18F FDG-PET correlates of motor neuron disease motor variants
2026-02-26 neurology 10.64898/2026.02.24.26347019
Top 0.1% (5.1%)
Show abstract

While 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is an established biomarker in amyotrophic lateral sclerosis (ALS), the metabolic correlates of motor neuron disease motor variants remain poorly defined. This is why we investigated patterns of cerebral glucose metabolism across the spectrum of motor neuron disorders (MND), including progressive muscular atrophy (PMA), primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS). We retrospectively included 18 PMA, ...

4
Functional neurological symptoms occur commonly in healthy adults: implications for the pathophysiology of FND
2026-02-28 neurology 10.64898/2026.02.26.26347208
Top 0.1% (4.7%)
Show abstract

ObjectivesFunctional neurological symptoms which do not meet clinical definitions of functional neurological disorder (FND) are common in clinical practice. Understanding the distinction between these benign functional symptoms and FND is crucial in defining FND as an entity for study, and as a clinical syndrome. We aimed to measure the frequency of functional symptoms in people who do not have FND. MethodsA survey was administered to 95 clinicians who attended an international conference on F...

5
EARLY-ALS: A Multicentre Study on Presymptomatic and Prodromal Amyotrophic Lateral Sclerosis
2026-01-30 neurology 10.64898/2026.01.30.26345123
Top 0.2% (4.5%)
Show abstract

Neurodegenerative diseases often feature a prolonged presymptomatic phase during which pathological processes evolve before overt clinical manifestation. In Amyotrophic lateral sclerosis (ALS), defining this prodromal period is critical for identifying early disease features and the optimal window for intervention, yet it remains poorly characterised. In this cross-sectional study, we compared 475 ALS patients with 285 controls recruiting across 20 ALS expert centres in Germany and Switzerland....

6
Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR-PSP)
2026-01-30 neurology 10.64898/2026.01.25.26344786
Top 0.2% (4.3%)
Show abstract

BackgroundProgressive supranuclear palsy (PSP) is a rare and devastating tauopathy with limited global data. Given Indias large population, genetic diversity, and clinical heterogeneity, large multicenter datasets are crucial to enrich global understanding of PSP. ObjectiveTo characterize the demographic, clinical, and phenotypic profiles of a large multicenter Indian PSP cohort. MethodsSubjects fulfilling MDS-PSP criteria were prospectively recruited across movement disorders centers (2021-20...

7
Assessing and quantifying gait deviations in STXBP1-related disorder using three-dimensional gait analysis.
2026-03-07 neurology 10.64898/2026.03.02.26346982
Top 0.2% (3.9%)
Show abstract

Background and objectives STXBP1-related disorder (STXBP1-RD), caused by pathogenic variants in the STXBP1 gene, is a rare neurodevelopmental condition, characterized by early-onset seizures, developmental delay, intellectual disability (ID), and prominent motor dysfunction. Despite the high prevalence of motor symptoms, systematic gait characterization remains limited. We therefore aimed to quantitively assess gait in individuals with STXBP1-RD. Methods In this cross-sectional study, we include...

8
Evaluation of Clinical Outcomes of Riluzole monotherapy and Riluzole based adjunctive interventions in Amyotrophic Lateral Sclerosis: A meta analytic and unsupervised clustering approach
2026-02-26 neurology 10.64898/2026.02.24.26346710
Top 0.3% (3.8%)
Show abstract

Amyotrophic Lateral Sclerosis (Lou Gehrigs disease) is a progressive neurodegenerative disease affecting hundreds of thousands of people worldwide. It is characterized by the degeneration of the neurons in the brain and spinal cord of the patients, leading to a loss of control of muscles. Over time, without nerves to stimulate them muscles tend to atrophy. ALS may occur sporadically or run in families; many mutations have been identified for the latter. Treatment of ALS is mostly limited to thre...

9
Chitinases in tear fluid of patients with Amyotrophic Lateral Sclerosis
2026-02-05 neurology 10.64898/2026.02.04.26345568
Top 0.3% (3.8%)
Show abstract

BackgroundChitinases, including chitotriosidase (CHIT1) and chitinase-3-like protein 1 (CHI3L1), are markers of neuroinflammation, a key process in amyotrophic lateral sclerosis (ALS). Tear fluid (TF) can be collected non-invasively and may represent a promising alternative to CSF or blood to study chitinases. MethodsTF was collected from 50 ALS patients and 50 control subjects using Schirmer strips. CHIT1 and CHI3L1 levels in TF, serum, and CSF were quantified using ELISA. Serum NfL was measur...

10
The Study Protocol for GENESIS: GENEral population normS - An International Survey
2026-01-29 neurology 10.64898/2026.01.27.26344920
Top 0.3% (3.8%)
Show abstract

BackgroundChronic autoimmune diseases such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and Thyroid Eye Disease (TED) impose a considerable burden on affected individuals. Patient-reported outcome measures (PROMs)--both disease-specific and generic--are widely used to assess functioning, quality of life, and treatment effects in these populations. However, most PROMs currently lack reference values derived from the general population, limiting t...

11
Evidence of Accumulating Neurophysiologic Dysfunction in Persistent Post-COVID Fatigue
2025-12-21 neurology 10.64898/2025.12.19.25342669
Top 0.4% (3.7%)
Show abstract

A major consequence of the COVID-19 pandemic has been the emergence of post-COVID syndrome (PCS), and more specifically, post-COVID fatigue (pCF), with an estimated prevalence of [~]2%. We previously showed that, compared to healthy controls, people with pCF exhibit changes in muscle physiology, cortical circuitry, and autonomic function. Here we present results from a cohort of people with pCF (N=145), between 12 weeks and 45 months post-infection. We report self-perception of fatigue; objecti...

12
Long-Term Slowing of Progression in Huntington's Disease with Pridopidine Treatment
2026-02-17 neurology 10.64898/2026.02.13.26345490
Top 0.4% (3.6%)
Show abstract

BackgroundHuntingtons disease (HD) causes progressive loss of function, cognition, and motor control, with no approved therapy yet shown to slow disease progression. In the PROOF-HD phase 3 trial, pridopidine did not meet the primary or key secondary outcomes in the overall population, but participants who remained off antidopaminergic medications (ADMs) showed benefits compared to placebo during the double-blind phase. Whether such benefits continue with longer duration treatment and how they c...

13
Minocycline in Acute Traumatic Spinal Cord Injury: A Systematic Review and Exploratory Meta Analysis of Preclinical and Clinical Evidence
2025-12-22 neurology 10.64898/2025.12.19.25342695
Top 0.4% (3.6%)
Show abstract

BackgroundTraumatic spinal cord injury (SCI) is a major cause of long-term neurological disability, with limited pharmacological therapies targeting secondary inflammatory and neurodegenerative injury mechanisms. Minocycline, a tetracycline derivative with anti-inflammatory and neuroprotective properties, has been investigated in both experimental and clinical settings; however, its therapeutic efficacy in acute traumatic SCI remains uncertain. MethodsA systematic review was conducted in accord...

14
Biofluid Biomarkers of Ischaemic Penumbra in Acute Ischaemic Stroke: A Systematic Review and Meta-Analysis
2026-03-03 neurology 10.64898/2026.03.03.26347352
Top 0.4% (3.6%)
Show abstract

IntroductionThe ischaemic penumbra is the principal therapeutic target in acute ischaemic stroke (AIS). Although perfusion imaging enables identification of salvageable tissue, its availability is limited and iodinated contrast exposure carries risk. Validated blood-based biomarkers could serve as scalable surrogates for imaging-defined penumbra. ObjectiveWe conducted a systematic review and meta-analysis to assess the association between blood-based biomarkers reported in the literature and th...

15
Autoimmune encephalitis patients identified among individuals attending Swedish memory clinics
2026-02-14 neurology 10.64898/2026.02.09.26345301
Top 0.5% (3.6%)
Show abstract

IntroductionNeurodegenerative dementia syndromes are severely debilitating, progressive and increasing in incidence with an ageing population. A treatable differential diagnosis to neurodegenerative dementia is autoimmune encephalitis (AE), but AE patients are often misdiagnosed, delaying treatment. Previous work in the Netherlands has shown that 0.8% of patients with suspected neurodegenerative dementia suffer from AE. In Sweden, there is considerable variability in the prevalence of AE, possib...

16
Distinct Inflammatory Profiles in Angiography-Negative Subarachnoid Hemorrhage: A Focused Case Series
2026-03-04 neurology 10.64898/2026.03.02.26347456
Top 0.5% (3.6%)
Show abstract

ObjectiveTo compare early cerebrospinal fluid (CSF) cytokine profiles in intracerebral hemorrhage (ICH) versus subarachnoid hemorrhage (SAH), with a focus on angiography-negative SAH (anSAH). MethodsWe conducted a retrospective observational cohort study of adults with spontaneous hemorrhagic stroke (ICH or SAH). For cytokine analyses, we included patients with external ventricular drains (EVDs) and analyzed the first CSF sample obtained within 72 hours of symptom onset. Cytokines were measured...

17
Cerebrospinal fluid haemoglobin as a monitoring biomarker for secondary brain injury after aneurysmal subarachnoid haemorrhage: prospective international multicentre validation study (HeMoVal)
2026-01-16 neurology 10.64898/2026.01.15.26343790
Top 0.5% (3.5%)
Show abstract

ObjectivesTo validate whether cerebrospinal fluid oxyhaemoglobin (CSF-Hb), measured from external ventricular or lumbar drains, is associated with secondary brain injury (SAH-SBI) after aneurysmal subarachnoid haemorrhage (aSAH), and to assess its value as a real-time monitoring biomarker. DesignPreregistered multicentre prospective observational cohort study. SettingEight neurosurgical tertiary centres in Switzerland, Germany, and Austria, between August 2021 and June 2024. Participants366 p...

18
Caregiver differentiation between dystonia and spasticity in cerebral palsy
2026-02-26 neurology 10.64898/2026.02.24.26347000
Top 0.6% (3.1%)
Show abstract

BackgroundDystonia is a debilitating movement disorder that is difficult to assess when co-existing with spasticity, as is typical in cerebral palsy (CP). Querying caregivers about their childrens movements is known to increase clinical dystonia identification. However, beyond identification, determining whether dystonia is the predominant vs. accompanying movement feature in a child with CP can guide clinical decision making, particularly regarding surgical candidacy. ObjectiveTo determine whe...

19
Skin Seed Amplification Assay differentiates Multiple System Atrophy from Parkinson's Disease
2025-12-15 neurology 10.64898/2025.12.11.25341627
Top 0.6% (3.0%)
Show abstract

BackgroundMisdiagnoses of multiple system atrophy (MSA) and Parkinsons disease (PD) remain common due to overlapping clinical features. ObjectiveTo develop and assess a skin -synuclein seed amplification assay (Syn-SAA) for detecting pathological -synuclein and distinguishing MSA from PD. MethodsIn this blinded, cross-sectional study conducted across two laboratories, 308 skin biopsies from 117 participants were analyzed using a standardized Syn-SAA protocol. The cohort included 42 PD, 31 MSA,...

20
Quantified Brain Atrophy and Risk of Severe Mass Effect in Acute Ischemic Stroke
2026-03-04 neurology 10.64898/2026.02.27.26346805
Top 0.6% (2.9%)
Show abstract

BackgroundLarge middle cerebral artery (MCA) infarctions can result in life-threatening cerebral edema. Quantitative brain atrophy may improve risk stratification for severe edema. We examined whether quantitative brain atrophy is associated with severe midline shift after large ischemic stroke and whether incorporating atrophy improves prediction beyond established clinical and radiographic predictors. MethodsThis was a retrospective observational cohort study of patients with [≥][1/2] MCA ...